Clinical Trial Update: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares Lutetium-177Lu oxodotreotide with Octreotide LAR in patients with gastroenteropancreatic neuroendocrine tumors, examining effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177Lu oxodotreotide (lutetium-177 dotatate)
• Octreotide LAR (octreotide long-acting release)

Snippet

Sponsor: Sinotau Pharmaceutical Group | Conditions: Neuroendocrine Tumors | Phase 3 | Status: ACTIVE_NOT_RECRUITING